scout
|Videos|November 13, 2017

Comparing Alectinib Versus Crizotinib in ALK+ NSCLC

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses results of the ALEX clinical trial, which compared alectinib (Alecensa) versus crizotinib (Xalkori) in patients with ALK+ non–small cell lung cancer (NSCLC).

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME